Drug Search Results
More Filters [+]

GC-1109

Alternative Names: gc-1109, gc1109, gc 1109
Latest Update: 2023-10-09
Latest Update Note: News Article

Product Description

GC1109 targets as its antigen the anthrax toxin which, in infection, serves as a receptor binder.

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Green Cross
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GC-1109

Countries in Clinic: Korea

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Anthrax

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GC1109

P2

Completed

Anthrax

2022-08-02

24%

Recent News Events